Targeted therapy in lung cancer: Are we closing the gap in years of life lost?

PURPOSE: Patients with non‐small cell lung cancer (NSCLC) that harbor driver mutations are associated with a cancer diagnosis at a younger age. While targeted therapies provide deep remissions and durable benefit in a subset of patients, it is unclear whether targeted therapies bridge the gap in yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Benjamin, David J., Haslam, Alyson, Gill, Jenny, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487872/
https://www.ncbi.nlm.nih.gov/pubmed/35315222
http://dx.doi.org/10.1002/cam4.4703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487872/
https://www.ncbi.nlm.nih.gov/pubmed/35315222
http://dx.doi.org/10.1002/cam4.4703

Ejemplares similares